Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF


Primary Symbol: V.BTI.H

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Perhaps the greatest piece of investment wisdom ever...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(17)
•••
Comment by fuzzyjron Jun 27, 2023 7:59pm
134 Views
Post# 35517509

RE:Perhaps the greatest piece of investment wisdom ever...

RE:Perhaps the greatest piece of investment wisdom ever..."
 
•••
Post by TailwindsRsrchon Jun 22, 2023 2:25pm
533 Views 
Post# 35509690

Perhaps the greatest piece of investment wisdom ever...

was when JD said, "you haven't lost anything if you don't sell." 

I drop into this chat once every 6 months or so just for fun. I guess those days are over as the company is kaput. To all of you who didn't lose money here, I feel very sorry that you listened to the bitter man's advice and rode this thing to zero. 

Even worse, we all know he put little to no money into this company. Just sad how many people he hurt while he exits with just shattered dreams but no real financial pain.

Here's my advice to everyone. Sell now so you can take the tax loss. You don't want to have to prove to the tax people that this is worthless. So, hit the bid before it's gone."

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities